Lakewood-Amedex Biotherapeutics Inc. (LABT) Stock Forecast
LABT analyst forecast
as of October 18, 2026- Analyst consensus
- —
- Price target
- $12.00 average of analyst targets
- Upside to target
- +1,969.0% from the latest close
- Next earnings
- November 12, 2026 EPS estimate $0.81
- 52-week range
- $0.58 – $8.65
LABT price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
LABT earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.81 | −$0.81 | −$0.81 | — | — | 1 |
| Current fiscal year (2026) | −$4.96 | −$4.96 | −$4.96 | −$0.84 | −490.5% | 1 |
| Next fiscal year (2027) | −$1.32 | −$1.32 | −$1.32 | −$4.96 | +73.4% | 1 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
LABT revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0 | $0 | $0 | — | 1 |
| Current fiscal year (2026) | $0 | $0 | $0 | — | 1 |
| Next fiscal year (2027) | $0 | $0 | $0 | 0.0% | 1 |
LABT EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
LABT EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.56 | −$0.56 | −$0.81 | −$0.81 | −$0.81 | +44.6% | 0 up · 1 down |
| Current fiscal year (2026) | −$2.52 | −$2.52 | −$4.96 | −$4.96 | −$4.96 | +96.8% | 0 up · 1 down |
| Next fiscal year (2027) | −$1.32 | −$1.32 | −$1.32 | −$1.32 | −$1.32 | 0.0% | 0 up · 0 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
LABT earnings surprises
Reported EPS vs the consensus estimate for the last 2 quarters; LABT beat in 0 of 1.
What analysts expect from LABT
The average price target is $12.00, 1,969.0% above the latest close of $0.58. Analysts expect earnings of −$4.96 per share for 2026, −490.5% from a year earlier. For 2027 the average estimate is −$1.32 per share. Lakewood-Amedex Biotherapeutics beat the EPS estimate in 0 of the last 1 quarters.
Related: LABT income statement, LABT key metrics, LABT chart. See the LABT stock overview for the latest quote and news.
LABT forecast FAQ
What is Lakewood-Amedex Biotherapeutics's price target?
The average analyst price target for Lakewood-Amedex Biotherapeutics is $12.00, 1,969.0% above the latest close of $0.58.
What is Lakewood-Amedex Biotherapeutics's EPS forecast?
Analysts forecast −$4.96 per share for 2026 (range −$4.96 to −$4.96); for 2027 the estimate is −$1.32.
When does Lakewood-Amedex Biotherapeutics report earnings?
Lakewood-Amedex Biotherapeutics is expected to report results for the quarter ending September 30, 2026 on November 12, 2026; the EPS estimate is $0.81.
Does Lakewood-Amedex Biotherapeutics usually beat earnings estimates?
Lakewood-Amedex Biotherapeutics reported EPS at or above the analyst estimate in 0 of the last 1 quarters.